Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai registered swift benefits from its acquisition of MGI Pharma with oncology revenues accounting for 10 percent of its global sales, Eisai CEO Haruo Naito told an Oct. 31 earnings conference